ABVC BIOPHARMA INC (ABVC) Fundamental Analysis & Valuation
NASDAQ:ABVC • US00091F3047
Current stock price
1.05 USD
+0.08 (+8.24%)
Last:
This ABVC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ABVC Profitability Analysis
1.1 Basic Checks
- In the past year ABVC has reported negative net income.
- In the past year ABVC has reported a negative cash flow from operations.
- ABVC had negative earnings in each of the past 5 years.
- ABVC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ABVC has a better Return On Assets (-23.16%) than 73.50% of its industry peers.
- With a decent Return On Equity value of -40.73%, ABVC is doing good in the industry, outperforming 69.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.16% | ||
| ROE | -40.73% | ||
| ROIC | N/A |
ROA(3y)-67.54%
ROA(5y)-92.57%
ROE(3y)-324.06%
ROE(5y)-329.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ABVC has a better Gross Margin (100.00%) than 99.81% of its industry peers.
- The Profit Margin and Operating Margin are not available for ABVC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ABVC Health Analysis
2.1 Basic Checks
- ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ABVC has been increased compared to 1 year ago.
- ABVC has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, ABVC has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -4.28, we must say that ABVC is in the distress zone and has some risk of bankruptcy.
- ABVC has a Altman-Z score (-4.28) which is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.07 indicates that ABVC is not too dependend on debt financing.
- ABVC has a Debt to Equity ratio of 0.07. This is comparable to the rest of the industry: ABVC outperforms 40.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.28 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
- ABVC has a Current Ratio of 0.51. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 0.51, ABVC is doing worse than 90.52% of the companies in the same industry.
- ABVC has a Quick Ratio of 0.51. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
- ABVC has a Quick ratio of 0.50. This is amonst the worse of the industry: ABVC underperforms 89.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.5 |
3. ABVC Growth Analysis
3.1 Past
- ABVC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.56%, which is quite impressive.
- The Revenue for ABVC has decreased by -99.61% in the past year. This is quite bad
EPS 1Y (TTM)73.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-339%
Revenue 1Y (TTM)-99.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ABVC Valuation Analysis
4.1 Price/Earnings Ratio
- ABVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. ABVC Dividend Analysis
5.1 Amount
- ABVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ABVC Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:ABVC (4/1/2026, 3:07:41 PM)
1.05
+0.08 (+8.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03
Earnings (Next)04-13 2026-04-13/amc
Inst Owners3.33%
Inst Owner Change9.03%
Ins Owners7.49%
Ins Owner Change0%
Market Cap26.71M
Revenue(TTM)2.00K
Net Income(TTM)-4.91M
Analysts43.33
Price TargetN/A
Short Float %1.2%
Short Ratio4.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 13356 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.21 | ||
| P/tB | 2.21 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.16% | ||
| ROE | -40.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% | ||
| FCFM | N/A |
ROA(3y)-67.54%
ROA(5y)-92.57%
ROE(3y)-324.06%
ROE(5y)-329.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | -4.28 |
F-Score5
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)32.44%
Cap/Depr(5y)179.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-339%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.48%
OCF growth 3YN/A
OCF growth 5YN/A
ABVC BIOPHARMA INC / ABVC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ABVC BIOPHARMA INC (ABVC) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ABVC.
Can you provide the valuation status for ABVC BIOPHARMA INC?
ChartMill assigns a valuation rating of 0 / 10 to ABVC BIOPHARMA INC (ABVC). This can be considered as Overvalued.
Can you provide the profitability details for ABVC BIOPHARMA INC?
ABVC BIOPHARMA INC (ABVC) has a profitability rating of 2 / 10.
Can you provide the financial health for ABVC stock?
The financial health rating of ABVC BIOPHARMA INC (ABVC) is 1 / 10.